VGX-3100: Therapeutic Vaccine for Cervical Cancer (HPV)
Prophylactic vaccines already approved (Merck & GSK)

Aimed at inducing natural immunity against HPV infection in naive individuals

Generate serum-neutralizing antibodies

Therapeutic vaccines

No therapeutic vaccine for HPV approved to date
Focused on women with active disease

Aimed at controlling disease progression

Induction of strong cell-mediated response

E6 and E7 proteins are expressed in most HPV-related (pre) cancerous tumors

Vaccine/therapeutic directed at HPV types 16 and 18 could potentially treat 71% of cervical cancers

VGX-3100 – Therapeutic Vaccine Targeting E6/E7 Proteins of HPV Types 16 and 18

Therapeutic Cervical Cancer DNA Vaccine (VGX-3100)
(HPV types 16 and 18)

Prophylactic Tumor Challenge



 
 
© 2008 VGX™ Pharmaceuticals. All rights reserved.